Childhood acute lymphoblastic leukemia (Q40637650)

22 September 2017

Childhood acute lymphoblastic leukemia (English)

1 reference

22 September 2017

1

Ching-Hon Pui

1 reference

22 September 2017

Mary V Relling

2

1 reference

PubMed ID

12196214

22 September 2017

Dario Campana

series ordinal

3

1 reference

PubMed ID

12196214

22 September 2017

William E Evans

series ordinal

4

1 reference

22 September 2017

1 June 2002

1 reference

Reviews in Clinical and Experimental Hematology

22 September 2017

1 reference

22 September 2017

6

1 reference

22 September 2017

2

1 reference

22 September 2017

161-80; discussion 200-2

1 reference

Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01.

22 September 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Childhood acute lymphoblastic leukaemia--current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Breakage and fusion of the TEL (ETV6) gene in immature B lymphocytes induced by apoptogenic signals

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Topoisomerase II inhibitor-related acute myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Methylenetetrahydrofolate reductase (MTHFR) polymorphisms and risk of molecularly defined subtypes of childhood acute leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

The methylenetetrahydrofolate reductase C677T gene polymorphism decreases the risk of childhood acute lymphocytic leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Racial differences in the survival of childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Long-term follow-up of the United Kingdom Medical Research Council protocols for childhood acute lymphoblastic leukaemia, 1980-1997. Medical Research Council Childhood Leukaemia Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Hematologic malignancies with t(4;11)(q21;q23)--a cytogenetic, morphologic, immunophenotypic and clinical study of 183 cases. European 11q23 Workshop participants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Prognostic significance of TEL/AML1 fusion transcript in childhood B-precursor acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Pharmacogenomics: translating functional genomics into rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Pharmacogenetics and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

High incidence of secondary brain tumours after radiotherapy and antimetabolites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Effect of altering conditions of the sequence method on baroreflex sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Association of CYP3A4 genotype with treatment-related leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

New definition of remission in childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Minimal residual disease in leukaemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Recombinant urate oxidase for the prophylaxis or treatment of hyperuricemia in patients With leukemia or lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Recombinant urate oxidase (rasburicase) in the prevention and treatment of malignancy-associated hyperuricemia in pediatric and adult patients: results of a compassionate-use trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Meeting report: International Childhood ALL Workshop: Memphis, TN, 3-4 December 1997.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) acute lymphoblastic leukemia studies, 1982-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Long-term results of three randomized trials (58831, 58832, 58881) in childhood acute lymphoblastic leukemia: a CLCG-EORTC report. Children Leukemia Cooperative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Magnetic resonance imaging detection of avascular necrosis of the bone in children receiving intensive prednisone therapy for acute lymphoblastic leukemia or non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Bony morbidity in children treated for acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Secondary brain tumors in children treated for acute lymphoblastic leukemia at St Jude Children's Research Hospital.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. Associazione Italiana Ematologia Oncologia Pediatrica and the Berlin-Frankfurt-Münster groups.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Drug resistance in hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-0734.2002.00067.X

10.1046/J.1468-0734.2002.00067.X

21 January 2018

Identifiers

DOI

1 reference

22 September 2017

1 reference

PubMed ID

12196214